Meletios develops two complementary programs to prevent the virus from taking advantage of the host resources.
Meletios is developing a disruptive platform for new RNA biologics, Defective Viral Genomes (DVG), originating from the Institut Pasteur. The RNA sequences directly interfere with the protein expression machinery hijacked by viruses. Candidates have a broad spectrum potential and are under development for arboviruses (Dengue, Zika, Chikungunya). Once a virus is identified, it takes only a few months to identify a promising lead DVG candidate.
The most advanced drug candidate is a host targeting agent that has confirmed its broad-spectrum potential on influenza H1N1 and the whole coronavirus family, demonstrating an innovative dual antiviral and anti-inflammatory activity. This molecule has proved its safety in humans and next step in the Human proof of efficacy.